[High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients]
| Autor: | M C, Baranzelli, F, Pichon, B, Gourmel, M, N'Guyen, N, Deligny, M C, Demaille |
|---|---|
| Jazyk: | francouzština |
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male Dose-Response Relationship Drug Sarcoma Soft Tissue Neoplasms Middle Aged Clonazepam Drug Administration Schedule Granulocyte Colony-Stimulating Factor Feasibility Studies Humans Anticonvulsants Female Kidney Diseases Ifosfamide Nervous System Diseases Infusions Intravenous Antineoplastic Agents Alkylating Aged |
| Zdroj: | Bulletin du cancer. 84(2) |
| ISSN: | 0007-4551 |
| Popis: | Ifosfamide is one of the most efficient antimitotic in soft tissue sarcoma. To try to find a possible dose-effect, 10 patients with advanced pretraited relapsed soft tissue sarcoma received 15 g/m2/cycle ifosfamide in continuous infusion during 5 days. A pharmacokinetic study was done for 2 patients. All patients received growth factors, ondansetron and 8 clonazepam. Renal toxicity was evaluated after the first and the second cycle. Twenty two cycles were delivered to patients who have been already treated with ifosfamid (10 patients with 15 g/m2 to 54 g/m2, median 27 g/m2) or cis platinum (2 patients). No major renal or neurologic toxicity was observed; only subclinical modifications of urinary enzymes excretion were found. Two patients had visual hallucinations at the end of a cycle and just in the 2 following days; another presented a neuropathy of inferior limbs. Hematological toxicity was very limited. Pharmacokinetic study did not show induction mechanism at this dosage and with this type of administration. So ifosfamide 3 g/m2 during 5 days is feasible. The few level of complications observed is perhaps linked to the daily dose of 3 g/m2 instead of 4 g/m2 or more used in the other studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|